Cargando…
A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes
The current study aimed to evaluate the efficacy of sitagliptin vs. placebo in treating non-alcoholic fatty liver disease (NAFLD). In a triple-blind randomized clinical trial, we assigned 120 eligible subjects with NAFLD to receive daily dosing of 50 mg sitagliptin (n = 60) or the placebo (n = 60) f...
Autores principales: | Doustmohammadian, Azam, Nezhadisalami, Ahmad, Safarnezhad Tameshke, Fahimeh, Motamed, Nima, Maadi, Mansooreh, Farahmand, Mohammad, Sohrabi, Masoudreza, Clark, Cain C. T., Ajdarkosh, Hossein, Faraji, Amir Hossein, Nikkhah, Mehdi, Sobhrakhshankhah, Elham, Ebrahimi, Ramin, Zamani, Farhad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365981/ https://www.ncbi.nlm.nih.gov/pubmed/35966875 http://dx.doi.org/10.3389/fmed.2022.937554 |
Ejemplares similares
-
Favorable association between Mediterranean diet (MeD) and DASH with NAFLD among Iranian adults of the Amol Cohort Study (AmolCS)
por: Doustmohammadian, Azam, et al.
Publicado: (2022) -
Empirically-Derived Dietary Patterns in Relation to Non-Alcoholic Fatty Liver Diseases Among Adult Participants in Amol, Northern Iran: A Structural Equation Modeling Approach
por: Doustmohammadian, Azam, et al.
Publicado: (2022) -
Rural Residency has a Protective Effect and Marriage is a Risk Factor for NAFLD
por: Motamed, Nima, et al.
Publicado: (2016) -
Tissue Sampling through Endoscopic Ultrasound-Guided Fine Needle Aspiration versus Endoscopic Retrograde Cholangiopancreatographic Brushing Cytology Technique in Suspicious Malignant Biliary Stricture
por: Sobhrakhshankhah, Elham, et al.
Publicado: (2021) -
Dietary Acid Load (DAL), Glycated Hemoglobin A1c (HbA1c), and Metabolic Syndrome (MeS) Mediate the Association of the Adherence to the Dietary Approaches to Stopping Hypertension (DASH) and Mediterranean Diet (MeD) With Nonalcoholic Fatty Liver Disease
por: Doustmohammadian, Azam, et al.
Publicado: (2022)